-
AstraZeneca and Daiichi Sankyo’s Enhertu Gains New Indication Approval in China for HER2-Low Breast Cancer
•
Partners AstraZeneca (AZ, NASDAQ: AZN) and Daiichi Sankyo (TYO: 4568) have announced that their co-developed antibody drug conjugate (ADC), Enhertu (trastuzumab deruxtecan), has been granted a new indication approval in China. This marks the drug’s second approval in the country and is specifically for use as a monotherapy in treating…
-
US FDA Approves Additional Shipments of Qilu Pharmaceutical’s Cisplatin to Address Shortage
•
The US Food and Drug Administration (FDA) is maintaining its reliance on China-based Qilu Pharmaceutical for supplies of the essential chemotherapy drug, cisplatin. Following the initial import of four lots in May, an additional ten lots have been approved this month. The drugs are distributed by Canada-based Apotex and are…
-
Shanghai Fosun Pharmaceutical Submits Tenapanor Approval Application to China’s NMPA
•
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196), a China-based pharmaceutical company, has announced a market approval filing to the National Medical Products Administration (NMPA) in China for its in-licensed tenapanor. The drug is indicated for the control of hyperphosphatemia in adult patients with chronic kidney disease (CKD) who are…
-
DNE Group Launches $485 Million Fund for Life Sciences Park in Shanghai Pudong
•
China-based infrastructure investor DNE Group has revealed that it has raised a new fund worth over RMB 3.5 billion (USD 485 million) to establish a life sciences park in Shanghai’s Pudong district. The fund, which was opened in Q1 2023, is reportedly backed primarily by China-based insurance companies. The project,…
-
LianBio Secures Clinical Supply Agreement with AstraZeneca for SHP2 Inhibitor Trial
•
Sino-US biotech firm LianBio (OTCMKTS: LIANY) has announced the signing of a clinical supply agreement with UK pharmaceutical giant AstraZeneca (AZ, NASDAQ: AZN). The agreement facilitates LianBio’s plan to test the combination of its pipeline SHP2 inhibitor, BBP-398, with AstraZeneca’s Tagrisso (osimertinib) in a Phase I clinical trial for patients…
-
Medidata Partners with ECCO and GoBroad to Transform Cancer Trials with Digital Tech
•
Medidata, a wholly owned subsidiary of France firm Dassault Systèmes (EPA: DSY), has announced a strategic partnership with the East Clinical Center of Oncology (ECCO) and GoBroad Healthcare Group. The collaboration aims to explore the digital transformation of cancer clinical trials and enhance the clinical application of Rave EDC (Electronic…
-
Shanghai Circode Bio and Pfizer Collaborate to Explore Circular RNA Therapy Potential
•
Shanghai Circode Bio has entered into a partnership with US pharmaceutical giant Pfizer (NYSE: PFE) to explore the therapeutic potential of circular RNA (circRNA). This strategic collaboration aims to fully leverage Circode Bio’s unique circular RNA technology platform and combine it with Pfizer’s extensive expertise and experience in the pharmaceutical…
-
Kedrion Biopharma Achieves First Product Approval in China for Human Albumin
•
Italy-headquartered blood products specialist Kedrion Biopharma has announced that its subsidiary, Bio Products Laboratory (BPL), has received approval from China’s National Institutes for Food and Drug Control (NIFDC) to release human albumin into the Chinese market for the first time. This milestone follows a 2022 partnership established between Kedrion and…
